摘要
目的：观察改良Hyper—CVAD方案治疗高度侵袭性非霍奇金淋巴瘤的疗效和毒性反应。方法：21例高度侵袭性非霍奇金淋巴瘤患者接受改良Hyper—CVAD方案化疗，21—28天为1周期，连用2个周期以上评价疗效。结果：全组21例，总有效率为85．7％，其中CR13例（61．9％），PR5例（23．8％）。1、2年总生存率分别为76．2％、57．1％。不良反应主要为Ⅲ～Ⅳ度骨髓抑制和轻至中度胃肠道反应。结论：改良Hyper—CVAD方案治疗高度侵袭性非霍奇金淋巴瘤疗效较好，不良反应可以耐受，值得进一步探讨。
Objective： To evaluate the efficacy and toxicity of modified Hyper - CVAD regimen on highly invasive Non - Hodgkin＇s lymphoma. Methods：All 21 patients with highly invasive Non -Hodgkin＇s lymphoma were treated with modi- fied Hyper- CVAD regimen. 21 ~ 28 days consisted of one cycle, and all the patients received over two cycles of the chemotherapy. Results：In 21 cases, the overall response rate was 85.7%. There was a complete response in 13 cases （61.9%） ,partial response in 5 cases（23. 8% ） . The 1 - year and 2 - year overall survival rate were 76. 2% ,57. 1%, respectivly. Main toxicity were Ⅲ- Ⅳ degree bone marrow depression and mild gastrointestinal reactions. Conclusions： Modified Hyper- CVAD regimen can achieve a satisfied results in the treatment of highly invasive Non -Hodgkin＇s lymphoma with well tolerated toxicity. Modified Hyper - CVAD regimen need further study.
出处
《航空航天医学杂志》
2013年第9期1052-1054,共3页
Journal of Aerospace medicine
